

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

1543

RECEIVED

MAY 23 2002

TECH CENTER 1800/2800

|   |                        |                          |                  |
|---|------------------------|--------------------------|------------------|
| Substitute for form 1449B/PTO   |                        | <b>Complete if Known</b> |                  |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |                        | Application Number       | 09/402,820       |
|   |                        | Filing Date              | October 12, 1999 |
|   |                        | First Named Inventor     | CHAIN, Daniel G. |
|   |                        | Group Art Unit           | 1543             |
|   |                        | Examiner Name            | P. Duffy         |
| Sheet 1 Of 2  | Attorney Docket Number | P-4815-US                |                  |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS |                       |  |                          |
|---|-----------------------|--|--------------------------|
| Examiner Initials*                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup>           |
| PAD   |                       | BUSCIGLIO J, ET AL, (1193) "Generation of b-amyloid in the secretory pathway in neuronal and nonneuronal cells" Proc. Natl. Acad. Sci. 90, 2092-2096   | <input type="checkbox"/> |
| PAD   |                       | GEDDES JW ET AL. (1999) "N-terminus truncated b-amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease" <i>Neurobiol of Aging</i> 20, 75-79.                           | <input type="checkbox"/> |
| PAD   |                       | HAAS C ET AL (1992) "Amyloid b-peptide is produced by cultured cells during normal metabolism" <i>Nature</i> 359, 322-325  | <input type="checkbox"/> |
| PAD   |                       | HAAS C ET AL. (1993) "Cellular processing of $\beta$ amyloid precursor protein and the genesis of amyloid $\beta$ -peptide." <i>Cell</i> 75, 1039-1042   | <input type="checkbox"/> |
| PAD   |                       | HIGGINS LS ET AL. (1996) "p3 b amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain." <i>Am. J. Pathol</i> 149, 585-596  | <input type="checkbox"/> |
| PAD   |                       | JOHNSON-WOOD K. ET AL. "Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease" <i>Proc Natl. Acad. Sci U.S.A.</i> 1997 Feb 18;94 (4): 1550-5   | <input type="checkbox"/> |
| PAD   |                       | LALOWSKI M (1996) "The nonamyloidogenic p3 fragment (amyloid $\beta$ 17-42) is a major constituent of Down's syndrome cerebellar preamyloid." <i>J Biol Chem</i> 271, 33623-31   | <input type="checkbox"/> |
| PAD   |                       | LARNER AJ (1999) "Hypothesis: amyloid b peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease." <i>Neurobiol. Of Aging</i> 20, 65-69.   | <input type="checkbox"/> |

RECEIVED  
MAY 20 2002  
TC 1700

15

Please type a plus sign (+) inside this box →

MAY 16 2002

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED  
MAY 23 2002

| Examiner | Signature   | Date Considered          |
|----------|---|--------------------------|
| PAD      | MASTERS CL ET AL. (1985) "Amyloid plaque core protein in Alzheimer's disease and Down syndrome." <i>Proc. Natl. Acad. Sci.</i> 82, 4245-9   | <input type="checkbox"/> |
| PAD      | MILLER DL ET AL. (1994) "Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease." <i>Archives of Biochemistry and Biophysics</i> 301, 41-52 | <input type="checkbox"/> |
| PAD      | NASLUND ET AL. (1994) "Relative abundance of Alzheimer A $\beta$ amyloid peptide variants in Alzheimer disease and normal aging." <i>Proc. Natl. Acad. Sci. USA</i> 91, 8378-8382               | <input type="checkbox"/> |
| PAD      | PIKE CJ ET AL. (1995) "Amino-terminal deletions enhance aggregation of $\beta$ -amyloid peptides in vitro." <i>J Biol Chem</i> 270, 23895-8   | <input type="checkbox"/> |
| PAD      | SEUBERT ET AL. (1992) "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids." <i>Nature</i> 359, 325-327   | <input type="checkbox"/> |
| PAD      | VIGO-PELFREY C ET AL. (1993) "Characterization of beta-amyloid peptide from human cerebrospinal fluid." <i>Neurochem</i> 61, 1965-8   | <input type="checkbox"/> |

RECEIVED  
MAY 20 2002  
TC 1700

| Examiner | Signature         | Date Considered |
|----------|-------------------|-----------------|
|          | PATRICIA A. DUFFY | 4-20-03         |

\* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.